Maximum quantity allowed is 999
请选择数量
CAS RN: 700874-72-2 | 產品號碼: G0639
| 產品號碼 | G0639 |
純度/分析方法 
|
>98.0%(T)(HPLC) |
| 分子式 / 分子量 | C__2__2H__1__9N__5O = 369.43 |
| 外觀與形狀（20°C） | Solid |
| 儲存條件
|
Refrigerated (0-10°C) |
| 儲存在惰性氣體下 | Store under inert gas |
| 應避免的情況 | Air Sensitive,Heat Sensitive |
| 包裝和容器
|
100MG-Glass Bottle with Plastic Insert （閲覽圖片） |
| CAS RN | 700874-72-2 |
| Reaxys-RN | 14275134 |
| MDL編號 | MFCD12923319 |
產品規格
| Appearance | White to Light yellow powder to crystal |
| Purity(HPLC) | min. 98.0 area% |
| Purity(Nonaqueous Titration) | min. 98.0 % |
| Melting point | 246.0 to 250.0 °C |
| NMR | confirm to structure |
性質
| 熔點 | 248 °C |
GHS
相關法規
運輸資料
| HS編碼* | 2933.49-000 |
Application
Galunisertib: An Oral and Selective TGF-β Receptor Type I (TGF-βR type I) Kinase Inhibitor
Transforming growth factor-beta (TGF-β) signaling regulates a wide range of biological processes. It has been reported that TGF-β plays an important role in tumorigenesis and migration of cancer cells.1) Galunisertib (LY2157299 monohydrate) is an oral and selective TGF-β receptor type I (TGF-βR type I) kinase inhibitor, and it has been used to study the role of TGF-β signaling in chemotherapy-induced expansion of cancer stem-like cells.2,3) (The product is for research use only.)
References
- 1) TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis
- 2) Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway
- 3) Targeting the TGFβ pathway with galunisertib, a TGFβRI small molecule inhibitor, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint blockade
產品文件 （部分產品的分析圖譜無法提供，敬請諒解。）
SDS
請選擇語言。
請求的SDS不可用。
如需更多幫助，請聯繫我們 。
產品規格
檢驗報告(CoA)及其他文檔
請輸入批號
輸入的批號不正確
示例 CoA
可下載CoA示例。注：該示例可能非最新批次的CoA。
目前沒有該產品的 CoA 示例。
分析圖譜
請輸入批號
輸入的批號不正確
很抱歉，您搜索的分析圖譜無法提供。